The ProVee System received FDA approval for treating BPH, offering a safe and effective procedure for symptom relief and quality of life improvement. The ProVIDE study showed significant improvement ...
SYNC-T demonstrated high efficacy in resolving bone metastases in metastatic prostate cancer, achieving an 87% overall response rate in a phase 1 trial. The therapy involves a minimally-invasive ...
Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...
“No doubt about it, this is unequivocally a positive trial by the rPFS criteria. Quite positive,” says A. Oliver Sartor, MD. Results from the phase 3 PSMAfore (NCT04689828) trial indicate that ...
IsoPSA test analyzes prostate cancer-specific structural variants of PSA protein to aid biopsy decisions in men over 50 with elevated PSA levels. The FDA approved IsoPSA based on a large-scale, ...
Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...
MRI outperformed micro-ultrasound in sensitivity and negative predictive value for prostate cancer detection. Micro-ultrasound offers a short learning curve and real-time lesion identification, ...
In patients with prostate cancer with biochemical recurrence following primary therapy, an intensified androgen blockade regimen consisting of apalutamide (Erleada) plus androgen deprivation therapy ...
In the EMBARK trial in patients with nonmetastatic hormone-sensitive prostate cancer, patients with good PSA responses at 37 weeks had their treatment suspended until their PSA started to rise again.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback